Public consultation on applications to be considered by the MSAC (March 2023)

Overview

Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on              30 - 31 March 2023.

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

It is anticipated that the below-mentioned applications will proceed to MSAC in March 2023. Consultation input must be received by no later than          Friday, 10 February 2023 for it to be considered by MSAC. A consultation survey form is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

Resubmissions:

1525.1 - Low dose rate brachytherapy for intermediate and high-risk prostate cancer

1595.1 - Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure therapy

1658.1 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib

New applications:

1549 - PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer

1700 - Totally thoracoscopic exclusion of the left atrial appendage for patients with non-valvular atrial fibrillation

1701 - Deep brain stimulation of the thalamus for the treatment of severe refractory epilepsy

1702 - Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours

1703 - Detection of measurable residual disease in patients with acute lymphoblastic leukaemia

1711 – Review of MBS items for subacromial decompression

1714 – National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A

1716 - Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment

1719 – Insertion of a bioabsorbable implant for nasal airway obstruction due to lateral wall insufficiency

1722 - Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma

1724 – Cardiac technical support services provided by industry employed allied health professionals

1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib

What happens next

Once the consultation closes, submissions will be compiled and considered by MSAC.

Once it has finalised its appraisal of an application for public funding, MSAC publishes a Public Summary Document (PSD). The PSD captures MSAC deliberations and key advice to the Minister, which is generally to either support funding; not support funding; or defer consideration. 

PSDs are generally published approximately three (3) months after the MSAC meeting at which the application was considered. The PSD can be located on the relevant application webpage on the MSAC website.